Market chatter intensifies: Social media users have highlighted CGTX as an under-the-radar biotech name with significant upside potential amid a broader list of speculative plays. Discussions note the stock trading at levels around $1 or lower, positioning it as a high-risk opportunity that some describe as a potential winner if catalysts materialize.
Investor groups emerge: Recent posts point to the formation of dedicated forums for CGTX holders to share updates and analysis on its pipeline developments. Sentiment remains cautiously optimistic, with participants emphasizing the stock's appeal for those seeking volatility-driven gains in the sector.
Broader context noted: Observers compare CGTX to other small-cap equities showing early momentum, though no single event dominates the conversation. Overall, the tone reflects interest in its long-term prospects without concrete price targets from participants.
Note: This discussion summary was generated from an AI condensation of post data.
Cognition Therapeutics Insider Trading Activity
Cognition Therapeutics insiders have traded $CGTX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CGTX stock by insiders over the last 6 months:
- JOHN BRENDAN DOYLE (Chief Financial Officer) purchased 10,000 shares for an estimated $11,299
- ANTHONY CAGGIANO (Chief Medical Officer) purchased 10,000 shares for an estimated $11,100
- LISA RICCIARDI (CEO & President) purchased 9,175 shares for an estimated $10,092
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Cognition Therapeutics Hedge Fund Activity
We have seen 31 institutional investors add shares of Cognition Therapeutics stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 2,042,815 shares (-99.2%) from their portfolio in Q1 2026, for an estimated $1,551,517
- DAVENPORT & CO LLC added 1,366,703 shares (+47.2%) to their portfolio in Q2 2026, for an estimated $1,571,708
- BLACKROCK, INC. added 293,631 shares (+30.3%) to their portfolio in Q2 2026, for an estimated $337,675
- JANE STREET GROUP, LLC removed 244,121 shares (-39.7%) from their portfolio in Q1 2026, for an estimated $185,409
- OMERS ADMINISTRATION CORP removed 159,600 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $121,216
- XTX TOPCO LTD added 158,576 shares (+426.0%) to their portfolio in Q1 2026, for an estimated $120,438
- HRT FINANCIAL LP added 152,999 shares (+inf%) to their portfolio in Q1 2026, for an estimated $116,202
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
